MODULATION OF D2-LIKE DOPAMINE RECEPTOR-MEDIATED STRIATAL SIGNALING PATHWAYS BY

D2 样多巴胺受体介导的纹状体信号通路的调节

基本信息

  • 批准号:
    7960145
  • 负责人:
  • 金额:
    $ 18.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-04 至 2010-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This subproject will investigate the functions of a striatal specific protein, RGS9-2, a member of the RGS family of G alpha GTPase accelerating proteins. Our previous data suggest that RGS9-2 is critical in the development of L-DOPA induced dyskinesia (LID) and tardive dyskinesia (TD). LID and TD are irreversible neurological motor toxicities of the pharmacotherapy of Parkinson's disease and psychotic disorders, respectively. While the etiology is unknown we have proposed a preliminary molecular model: D2-dopamine receptors (D2R) are a major target of both antipsychotic drugs and L-DOPA. RGS9-2 targets to D2DR via the RGS9 DEP domain and functionally compartmentalizes D2R in striatal neurons to block D2DR-mediated inhibition of NMDA receptors and Ca2+ channels. Prolonged drug-treatment produces compensatory alterations that disrupt RGS9-2 mediated cellular compartmentalization. These compensatory responses lead to abnormal basal ganglia signal processing and to drug-induced abnormal involuntary movements. Determining how such compartmentalization is disrupted will require a better understanding of the D2DR-RGS9-2 interaction which has been suggested by our colocalization studies. This effort will also be enhanced by a better understanding of the mechanisms by which RGS9-2 can modulate D2R responses. As a member of the RGS family, RGS9-2 can accelerate the deactivation kinetics of D2R responses, as we and others have demonstrated. It is unclear, however; if accelerating G protein turnover is the only mechanism by which RGS9-2 can modulate GPCR signal transduction mechanisms. Thus we will examine the effect of RGS9-2 on multiple signal transduction mechanisms of D2R including agonist dependent internalization and D2R activation the Mitogen Activated Protein Kinase (MAPK) pathways. Though the present proposal is restricted to characterizing the cellular function of RGS9-2, it is my expectation that the effort will provide us with the tools to test, validate, and expand our preliminary model for LID and TD in subsequent studies. Finally, we have identified multiple polymorphisms in the RGS9 gene that are enriched in schizophrenic and Parkinson's patients. We propose investigations of the effect of these polymorphisms on RGS9 function and expression.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Abraham Kovoor其他文献

Abraham Kovoor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Abraham Kovoor', 18)}}的其他基金

ROLE OF THE STRIATAL-SPECIFIC RGS PROTEIN RGS9-2, IN CELLULAR SIGNALING PATHWAYS
纹状体特异性 RGS 蛋白 RGS9-2 在细胞信号传导通路中的作用
  • 批准号:
    8360080
  • 财政年份:
    2011
  • 资助金额:
    $ 18.71万
  • 项目类别:
ROLE OF THE STRIATAL-SPECIFIC RGS PROTEIN RGS9-2, IN CELLULAR SIGNALING PATHWAYS
纹状体特异性 RGS 蛋白 RGS9-2 在细胞信号传导通路中的作用
  • 批准号:
    8167616
  • 财政年份:
    2010
  • 资助金额:
    $ 18.71万
  • 项目类别:
Development of A Novel Animal Model of Tardive Dyskinesia
迟发性运动障碍新动物模型的开发
  • 批准号:
    7982453
  • 财政年份:
    2010
  • 资助金额:
    $ 18.71万
  • 项目类别:
EMBRYONIC MOUSE STEM CELLS REPAIR BRAIN TOXICITY CAUSED BY ANTIPSYCHOTIC DRUGS
小鼠胚胎干细胞修复抗精神病药物引起的脑毒性
  • 批准号:
    7725258
  • 财政年份:
    2008
  • 资助金额:
    $ 18.71万
  • 项目类别:
MODULATION OF D2-LIKE DOPAMINE RECEPTOR-MEDIATED STRIATAL SIGNALING PATHWAYS BY
D2 样多巴胺受体介导的纹状体信号通路的调节
  • 批准号:
    7725160
  • 财政年份:
    2008
  • 资助金额:
    $ 18.71万
  • 项目类别:
MODULATION OF D2-LIKE DOPAMINE RECEPTOR-MEDIATED STRIATAL SIGNALING PATHWAYS BY
D2 样多巴胺受体介导的纹状体信号通路的调节
  • 批准号:
    7609982
  • 财政年份:
    2007
  • 资助金额:
    $ 18.71万
  • 项目类别:
A Genetic Test for Drug-Induced Dyskinesia Risk Determination
药物引起的运动障碍风险测定的基因测试
  • 批准号:
    7291637
  • 财政年份:
    2006
  • 资助金额:
    $ 18.71万
  • 项目类别:
A Genetic Test for Drug-Induced Dyskinesia Risk
药物引起的运动障碍风险的基因检测
  • 批准号:
    7159530
  • 财政年份:
    2006
  • 资助金额:
    $ 18.71万
  • 项目类别:
A Genetic Test for Drug-Induced Dyskinesia Risk Determination
药物引起的运动障碍风险测定的基因测试
  • 批准号:
    7313075
  • 财政年份:
    2006
  • 资助金额:
    $ 18.71万
  • 项目类别:

相似海外基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 18.71万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 18.71万
  • 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
  • 批准号:
    22590157
  • 财政年份:
    2010
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
  • 批准号:
    192724
  • 财政年份:
    2009
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
  • 批准号:
    7539253
  • 财政年份:
    2008
  • 资助金额:
    $ 18.71万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7676049
  • 财政年份:
    2007
  • 资助金额:
    $ 18.71万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7626881
  • 财政年份:
    2007
  • 资助金额:
    $ 18.71万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7333930
  • 财政年份:
    2007
  • 资助金额:
    $ 18.71万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    7034693
  • 财政年份:
    2006
  • 资助金额:
    $ 18.71万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    8391749
  • 财政年份:
    2006
  • 资助金额:
    $ 18.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了